Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study

F De Benedetti,N Wulffraat,R Jerath,N Ruperto,A Grom,H Brunner,A Martini,D Lovell,Y Kimura,J Wang,M Henrickson,Ak Kadva

doi:10.1186/1546-0096-12-s1-o13

F De Benedetti, N Wulffraat + Show 10 more

Open Access

https://doi.org/10.1186/1546-0096-12-s1-o13

Copy DOI

Journal: Pediatric Rheumatology	Publication Date: Sep 1, 2014
Citations: 1	License type: cc-by

Affiliation: Roche (United Kingdom)

Abstract

The TENDER clinical trial is a 3-part, 5-year, phase 3 study of tocilizumab (TCZ) in patients with active systemic juvenile idiopathic arthritis (sJIA). After 2 years of treatment, sJIA patients who have maintained clinically inactive disease (CID) for 3 months are given the option to participate in an alternative TCZ dosing regimen aimed at spacing the infusions and eventually withdrawing TCZ.

Highlights

The TENDER clinical trial is a 3-part, 5-year, phase 3 study of tocilizumab (TCZ) in patients with active systemic juvenile idiopathic arthritis
To qualify for the optional alternative dosing schedule, patients had to be in the study for a minimum of 2 years and had to achieve American College of Rheumatology JIA clinically inactive disease (CID) status
Among the 112 patients enrolled, 39 (35%) entered the optional alternative dosing regimen

Summary

Introduction

The TENDER clinical trial is a 3-part, 5-year, phase 3 study of tocilizumab (TCZ) in patients with active systemic juvenile idiopathic arthritis (sJIA).

Objectives

Results

Conclusion